dr chandrashekhar chavan chavan - Academia.edu (original) (raw)

Uploads

Papers by dr chandrashekhar chavan chavan

Research paper thumbnail of Outcomes of early vs. delayed combination medical therapy in LUTS/BPH patients with moderate to severe symptoms: Results from clinical trial simulations using individual IPSS trajectories

European Urology Supplements, 2019

Outcomes of early vs. delayed combination medical therapy in LUTS/BPH patients with moderate to s... more Outcomes of early vs. delayed combination medical therapy in LUTS/BPH patients with moderate to severe symptoms: Results from clinical trial simulations using individual IPSS trajectories

Research paper thumbnail of Patil DD, Pandit VS, Chavan CS, Pore SM. Fighting Counterfeit and Substandard Drugs at Periphery: The Utility of Basic Quality Control Tests. International Journal of Comprehensive Pharmacy 2012;3(3):1-3

Research paper thumbnail of Single dose cefazolin plus metronidazole versus existing multi-dose regimen for prophylaxis in caesarean section

Indian Journal of Pharmacology, 2012

Research paper thumbnail of Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression

World Journal of Urology, 2020

Purpose To evaluate the effect of delayed start of combination therapy (CT) with dutasteride 0.5 ... more Purpose To evaluate the effect of delayed start of combination therapy (CT) with dutasteride 0.5 mg and tamsulosin 0.4 mg on the risk of acute urinary retention or benign prostatic hyperplasia (BPH)-related surgery (AUR/S) in patients with moderate-to-severe lower urinary tract symptoms (LUTS) at risk of disease progression. Methods Using a time-to-event model based on pooled data from 10,238 patients from Phase III/IV dutasteride trials, clinical trial simulations (CTS) were performed to assess the risk of AUR/S up to 48 months in moderate-to-severe LUTS/BPH patients following immediate and delayed start of CT for those not responding to tamsulosin monotherapy. Simulation scenarios (1300 subjects/arm) were investigated, including immediate start (reference) and alternative delayed start (six scenarios 1–24 months). AUR/S incidence was described by Kaplan–Meier survival curves and analysed using log-rank test. The cumulative incidence of events as well as the relative and attributab...

Research paper thumbnail of Outcomes of early vs. delayed combination medical therapy in LUTS/BPH patients with moderate to severe symptoms: Results from clinical trial simulations using individual IPSS trajectories

European Urology Supplements, 2019

Outcomes of early vs. delayed combination medical therapy in LUTS/BPH patients with moderate to s... more Outcomes of early vs. delayed combination medical therapy in LUTS/BPH patients with moderate to severe symptoms: Results from clinical trial simulations using individual IPSS trajectories

Research paper thumbnail of Patil DD, Pandit VS, Chavan CS, Pore SM. Fighting Counterfeit and Substandard Drugs at Periphery: The Utility of Basic Quality Control Tests. International Journal of Comprehensive Pharmacy 2012;3(3):1-3

Research paper thumbnail of Single dose cefazolin plus metronidazole versus existing multi-dose regimen for prophylaxis in caesarean section

Indian Journal of Pharmacology, 2012

Research paper thumbnail of Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression

World Journal of Urology, 2020

Purpose To evaluate the effect of delayed start of combination therapy (CT) with dutasteride 0.5 ... more Purpose To evaluate the effect of delayed start of combination therapy (CT) with dutasteride 0.5 mg and tamsulosin 0.4 mg on the risk of acute urinary retention or benign prostatic hyperplasia (BPH)-related surgery (AUR/S) in patients with moderate-to-severe lower urinary tract symptoms (LUTS) at risk of disease progression. Methods Using a time-to-event model based on pooled data from 10,238 patients from Phase III/IV dutasteride trials, clinical trial simulations (CTS) were performed to assess the risk of AUR/S up to 48 months in moderate-to-severe LUTS/BPH patients following immediate and delayed start of CT for those not responding to tamsulosin monotherapy. Simulation scenarios (1300 subjects/arm) were investigated, including immediate start (reference) and alternative delayed start (six scenarios 1–24 months). AUR/S incidence was described by Kaplan–Meier survival curves and analysed using log-rank test. The cumulative incidence of events as well as the relative and attributab...

Log In